Health

STAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 22/10/2026, 12:36:25 UTC.

Briefings

Telehealth platforms have begun marketing off-label GLP-1 prescriptions for alcohol use disorder, bypassing FDA approval. Eli Lilly is testing brenipatide for alcohol use disorder, while Baseline Therapeutics and Altimmune are developing and testing GLP-1 agonists for multiple addictions. This represents a significant shift from the previous two decades of waiting for formal approval.

Key points

• Eli Lilly is investigating brenipatide for alcohol use disorder as part of its GLP-1 drug portfolio.
• Telehealth platforms have begun marketing off-label GLP-1 prescriptions for alcohol use disorder and other addictions.

Context

Telehealth platforms specializing in addiction treatment are now marketing off-label GLP-1 prescriptions, marking a shift from the previous two decades of waiting for FDA approval. This development highlights a rapid evolution in addiction medicine treatment approaches.

Limitations

Evidence is limited to reported marketing activities and company investigations; specific approval timelines remain uncertain. Preprint status and lack of controlled clinical trial data limit definitive conclusions.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 22/10/2026, 12:45:16 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeicun3dm3fvnxlct6ybk5slpcpwmkidcvggtd5scjlynitapinoq7y